Core Insights - Carlsmed, Inc. has appointed Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately, to enhance its leadership team post-IPO [1][3] - Ms. Kamocsay has over 20 years of corporate legal experience in the life sciences and technology sectors, previously serving in significant legal roles at Akoya Biosciences, Rubius Therapeutics, and Progress Software [2][3] - The company aims to strengthen its corporate governance and legal strategy as it prepares for the launch of its cervical commercial product in 2026 [3][5] Company Overview - Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions, with a mission to improve healthcare outcomes and reduce costs associated with spine surgery [4]

Core Insights - Carlsmed, Inc. has been added to the Russell 2000 Index, effective after market close on September 22, 2025, marking a significant milestone following its IPO in July 2025 [1][2] - The inclusion in the Russell 2000 Index is seen as validation of Carlsmed's differentiated business model and growth potential, enhancing its visibility among investors [2] Company Overview - Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions, aiming to improve healthcare outcomes and reduce costs associated with spine surgery [3] Industry Context - The Russell 2000 Index represents approximately 10 percent of the total market capitalization of the broader Russell 3000 Index, which is widely utilized by investment managers and institutional investors for benchmarking [2] - Approximately $9 trillion in assets are benchmarked against Russell's U.S. indexes, indicating the significance of the Russell 2000 Index in the investment landscape [2]

Core Insights - Carlsmed, Inc. reported a revenue of $12.1 million for Q2 2025, marking a 99% year-over-year growth from $6.1 million in Q2 2024 [1][3] - The company anticipates full-year revenue to be between $45.5 million and $47.5 million, representing a growth of 67% to 75% compared to 2024 [4] Financial Performance - Gross profit for Q2 2025 was $8.9 million, up from $4.6 million in Q2 2024, with a gross margin of 73.4% compared to 75.0% in the prior year [3] - Operating expenses increased to $15.4 million in Q2 2025 from $10.9 million in Q2 2024, driven by higher sales and marketing costs [3] - Net loss for Q2 2025 was $6.8 million, slightly higher than the $6.3 million loss in Q2 2024 [3] Technology and Market Position - The growth in revenue was attributed to the increased adoption of the AI-enabled aprevo technology platform, which is recognized for improving patient outcomes compared to traditional devices [2] - Carlsmed successfully completed its first personalized cervical spine surgery using the aprevo platform in July 2025, with plans for a commercial launch in 2026 [2][3] Cash Position - As of June 30, 2025, Carlsmed had cash and cash equivalents of $33.5 million, bolstered by $93.5 million in net proceeds from its initial public offering in July 2025 [3]